Louise Chen

I wanted to ask you about TEPEZZA and your thoughts on another potential competitor coming to market and then also where you stand with AMG seven thirty two for TED.

what type of share gains you expect for Anidocel in the fourth-line setting if you're approved, especially in light of competition from entrenched players